Fej-nyaki daganatok: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• PD-1 70
• PD-L1 42
• TP53 7
• EGFR 33
• PI3K 6
• STAT3 1
• BRAF 0
• AKT 2
• mTOR 0
• HER2 6
• RET 0
• MAPK 0
• ERK 0
• STING 0
• PTEN 1
• TERT 0
• CTNNB1 0
• JAK 1
• CTLA-4 4
• NRF2 0
• MYC 0
• VEGF 4
• YAP 1
• HIF-1 0
• MET 3
• AMPK 0
• CLDN18 0
• IL-6 2
• JNK 0
• PARP 1
• FGFR 1
• GPX4 0
• B7-H3 5
• COX-2 0
• LAG-3 2
• TROP2 5
• EZH2 0
• MEK 0
• METTL3 0
• CD47 1
• PIK3CA 4
• CDK4/6 2
• NLRP3 0
• ATM 0
• PKM2 0
• TNF 0
• FAK 0
• MMP-9 0
• PPAR 0
• PSMA 1
• TLR4 0
• BCL-2 0
• HSP90 0
• KRAS 0
• NOTCH1 0
• NTRK 1
• ALK 0
• CD40 1
• CDKN2A 2
• CXCR4 0

2+ intézményből 2, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetic Profiling and Telomere-Orchestrated Mechanisms in HPV+ Oropharyngeal Cancer (EPiTOME-M)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 268 569 EUR· until 2028. nov.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Endoscopic tissue time machine (EPIC)

  King's College London· London, Egyesült Királyság· EU contribution 2 273 033 EUR· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  From Whisper to Voice: Real-Time on-Device Assistive AI Technology for Human Connection (Whispp)

  Whispp Bv· Leiden, Hollandia· EU contribution 2 498 319 EUR· until 2028. máj.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  INHIBITING RESISTANCE TO IMMUNOTHERAPY IN HEAD&NECK CANCER BY TARGETING NETRIN-1 (NeckNET)

  Netris Pharma Sas· Lyon, Franciaország· EU contribution 7 248 398 EUR· until 2030. máj.· 4 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  Early clinical development of first-in-class EGL-001 targeting Tregs in head and neck squamous cell carcinoma, supported by AI-based pathomics (NEOTREG)

  Egle Therapeutics· Suresnes, Franciaország· EU contribution 7 999 120 EUR· until 2028. nov.· 4 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  FIRST-IN-CLASS BIOLOGICALLY TARGETED RADIOTHERAPY FOR HEAD AND NECK CANCERS (HNCS) (BIOTARGET0010)

  Universidad de Granada· Granada, Spanyolország· EU contribution 7 591 998 EUR· until 2030. nov.· 3 countries

• European Commission (Horizon Europe) · HORIZON-IA

  Unified digital platform for multimodal, multiscale, broadband, hyperspectral imaging (PHOTOMIX)

  Cy.r.i.c Cyprus Research and Innovation Center Ltd· Lefkosia, Ciprus· EU contribution 4 994 238 EUR· until 2029. nov.· 6 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Morphomolecular diagnostics of head and neck cancer (LEAN)

  King's College London· London, Egyesült Királyság· EU contribution 150 000 EUR· until 2027. ápr.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Virus-Inspired Colorectal Cancer Treatment through an Orally Administered Vaccine (VICTORY)

  Universitaetsklinikum Aachen· Aachen, Németország· EU contribution 150 000 EUR· until 2026. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Label-Free Raman Approaches for Patient-Specific Biochemical Tumor Mapping to Monitor Personalized Anticancer Resistance Simulation (RAMPART)

  Politecnico di Milano· Milano, Olaszország· EU contribution 209 483 EUR· until 2027. máj.· 3 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 12 running projects, newest first. Listed amounts together: 36,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

  NCT06980038· National Cancer Institute (NCI)· Forrás

• A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

  NCT06544655· Bristol-Myers Squibb· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 84
• Organoids 23
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 13
• Gene Expression Profiling 244
• Sequence Analysis, RNA 26
• Whole Genome Sequencing 7
• Exome Sequencing 22
• Proteomics 65
• Metabolomics 43
• Mass Spectrometry 14
• Flow Cytometry 56
• Immunohistochemistry 333
• Liquid Biopsy 34
• Circulating Tumor DNA 57
• Xenograft Model Antitumor Assays 307
• Positron-Emission Tomography 83
• Magnetic Resonance Imaging 276
• Machine Learning 232
• Deep Learning 187
• Cohort Studies 296
• Genome-Wide Association Study 55

• Causal effects of antihypertensive drugs on thyroid diseases: A trans-ancestry drug-target Mendelian randomization study.

  Medicine (Baltimore), 2026. okt.

• Causal association between fibroblast growth factors (FGFs) and gastric cancer: A two-sample Mendelian randomization study.

  Int J Biol Markers, 2026. okt.

• Association Between Oral Cavity Cancer and Lymphoma: A Bidirectional Mendelian Randomization Analysis.

  Oral Health Prev Dent, 2026. aug.

• Causal Association Between Antidepressant Use and Thyroid Disease Risk: A Two-Sample Mendelian Randomization Study.

  Actas Esp Psiquiatr, 2026. aug.

• A Two-Sample Mendelian Randomisation Analysis of the Oral Microbiome and Oral/Oropharyngeal/Tongue Cancers.

  Oral Health Prev Dent, 2026. aug.

• Multi-Omics Profiling Identifies Novel Therapeutic Targets and Pathobiological Mechanisms in Oral Cancer.

  J Cell Mol Med, 2026. aug.

• Deciphering the Relationship Between Alcohol Consumption, Oropharyngeal Cancers, and Socioeconomic Determinants.

  Alcohol Clin Exp Res (Hoboken), 2026. aug.

• Blood Manganese and Risk of Squamous Cell Carcinomas of the Head and Neck.

  JAMA Otolaryngol Head Neck Surg, 2026. aug.

• Exploring the potential causal relationship between lipid metabolism and oral carcinoma in situ: A 2-sample Mendelian randomization study.

  Medicine (Baltimore), 2026. júl.

• Genetically predicted vitamin D levels and risk of head and neck cancer: a mendelian randomization study.

  Cancer Causes Control, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.